Navigation Links
CombinatoRx and Neuromed Sign Merger Agreement
Date:7/2/2009

    - Merger to Create a Sustainable Biotechnology Company: Brings Together
    Significant Product Assets, Unique Discovery Capabilities and Financial
    Resources -

CAMBRIDGE, MA and VANCOUVER, BC, July 2 /PRNewswire/ - CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced they have entered into a definitive merger agreement under which CombinatoRx and Neuromed will merge in an all-stock transaction. Under the terms of the merger agreement, CombinatoRx is expected to issue approximately 36 million new shares of its common stock to Neuromed stockholders with each party owning approximately 50% of the voting power of the merged organization upon closing. Relative ownership of CombinatoRx will then be adjusted based upon the outcome of the FDA's review of the NDA product candidate, Exalgo(TM).

This merger brings together the product assets and financial resources of both organizations, including potential Exalgo(TM) milestones and royalty revenue and Neuromed's proven drug development expertise, with the CombinatoRx portfolio of product candidates and its unique drug discovery capabilities. The rights to Exalgo(TM), designed to be a once-daily, oral hydromorphone treatment seeking FDA approval for chronic to severe pain, were recently acquired by Mallinckrodt Inc., a subsidiary of Covidien plc, for $15 million in upfront payments, additional development funding of up to $16 million to cover internal and external costs associated with Exalgo, an approval milestone of $30 million, which could potentially increase up to $40 million, and tiered royalties on Exalgo(TM) net sales after approval. Neuromed has filed a New Drug Application for Exalgo(TM) with the FDA, which has a November 22, 2009 PDUFA review date.

"By combining forces with Neuromed
'/>"/>

SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
7. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
8. $10 Million Gift to Transform Neuromedicine at URMC
9. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
10. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
11. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... July 13, 2014 The federal court ... ) filed against Johnson & Johnson’s Ethicon, Inc. ... which is expected to get underway next month. According ... U.S. District Court, Southern District of West Virginia on ... on August 7, 2014 at 3:00 p.m. July selection ...
(Date:7/13/2014)... Max International has recently ... be the featured guest at its Charity Exhibition and ... Attendees will learn about Max’s health products and ... basketball games and perform in a 3 point shoot-out. ... and energy-boosting supplements , has recently announced former NBA ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its lace ... Recently, the company has announced its new selection of ... all these outfits are available at discounted prices (from ... supplier is now offering similar discounts for many other ... many other designs for sale, including flower girl dresses, ...
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... WASHINGTON, March 28 Thousands of epilepsy advocates, caregivers, ... celebrities at the nation,s Capitol today to support the ... two years, the event has raised more than $2 ... event is expected to increase those numbers significantly. Money ...
... could replace anti-clotting drug warfarin for many patients, researchers ... implanted device may soon replace the anti-clotting drug warfarin ... with atrial fibrillation, a new study suggests. , People ... stroke, the researchers noted, and typically need to take ...
... in era of rising costs , , FRIDAY, March 27 (HealthDay ... national health care reform when she was first lady in ... are working -- are without health insurance. , That finding ... a state-by-state picture of people foregoing insurance because of rising ...
... Drug-eluting stents were safe and superior to bare metal ... "real-world" patients enrolled in a nationwide registry of cardiovascular ... , The findings were presented today at the ... Scientific Session. They also appear online in the ...
... (NYSE: NUS ) announced that more than 100,000 ... the company,s distributors and customers who have purchased Epoch Baobab ... company has donated $0.25 from the sale of every Epoch ... Foundation,s Seeds of Hope reforestation project. "When someone purchases a ...
... Earnings Guidance to a Minimum of $0.25 per diluted ... Service Corporation (Nasdaq: PRSC ) today announced ... December 31, 2008. Included in the results is ... related to the Company,s intangible assets, which, when added ...
Cached Medicine News:Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 2Health News:Video: Celebrities and Thousands of Walkers Unite at Nation's Capitol to Raise Awareness About Seizures and Epilepsy 3Health News:New Device Treats Common Heart Rhythm Disorder 2Health News:New Device Treats Common Heart Rhythm Disorder 3Health News:One in Five Working Adults Said to Lack Health Insurance 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Nu Skin Charitable Promotion Reaches Important Milestone: 100,000 Trees Donated to African Nation of Malawi 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 2Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 3Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 4Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 5Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 6Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 7Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 8Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 9Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 10Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 11Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 12Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 13Health News:Providence Service Corporation Releases Fourth Quarter and Audited Year End 2008 Results 14
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... 26, 2011 Vapotherm announced today the launch ... specifically for homecare and other low acuity environments. ... and European markets. Vapotherm,s Flowrest® ... home and other extended care environments.  According to ...
... 26, 2011 Omnicell, Inc . (NASDAQ: ... medication and supply management solutions and analytics software ... Victoria Hospital (RVH) selected Omnicell G4 solutions ... by Omnicell,s hallmark flexibility and functionality, RVH became ...
Cached Medicine Technology:Vapotherm Announces Commercial Launch of Flowrest® Homecare Device 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
The intended use of the percutaneous PREFACE Guiding Sheath is for the introduction of intravascular electrophysiology catheters into any cardiac chamber....
... EP Systems sells the popular transeptal ... needles. These products allow left atrial ... catheter ablation of left-sided arrhythmogenic substrates. ... others use it when a transaortic ...
Medicine Products: